Wet AMD is an eye disorder characterised by leaky vessels in the retina causing vision loss. Credit: PeopleImages/Shutterstock.com. Following years of regulatory setbacks that saw multiple rejections, ...

Biointron Biological has launched RushData, a new platform to support the process of antibody discovery for pharmaceutical and biotechnology companies employing AI and ML.

Misumi Americas makes US manufacturing strategic priority, the celebrity brand ambassador rise in pharma, AI in the hospital pharmacy, and more.

BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.

GSK's newly approved ROS1-positive NSCLC drug, Jideytro will now enter a lung cancer niche dominated by Pfizer’s Lorbrena.

BMS enhances its AI computing power with NVIDIA's DGX SuperPOD as big pharma race to stay competitive within the shifting global landscape.

Affinia Therapeutics has received FDA orphan drug designation for AFTX-201, a treatment in development for BAG3-associated DCM.

Samsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015.

Samsung Biologics is set to acquire PolyPeptide Group through an all-cash public tender offer valued at SFr1.46bn ($1.81bn).

Lundbeck has secured fast track designation from the US FDA for its investigational treatment, Lu AH69593, to treat narcolepsy.

If introduced, the 100% tariffs would apply to all generic drugs imported to the US, which make up 90% of the nation’s prescriptions.

Despite a lacklustre start to the year, Novartis seems to have overcome its financial slump, reporting operating profits in Q2 that exceeded analyst expectations. The Swiss drugma ...